PortfoliosStock ScreensStocksStockXcel

Galmed Pharmaceuticals Ltd

GLMD | US

0.60

USD

0.02

2.83%

GLMD | US

About Galmed Pharmaceuticals Ltd

Sector

Healthcare

Industry

Biotechnology

Earnings date

30/06/2024

As of date

20/03/2026

Close

0.60

Open

0.62

High

0.62

Low

0.58

Galmed Pharmaceuticals Ltd. a biopharmaceutical company focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol an oral therapy which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition it engages in the development of Amilo-5MER a 5 amino acid synthetic peptide methionine threonine alanine aspartic acid and valine. It has a license agreement with Samil Pharma. Co. Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv Israel.

View Less

GLMD | US

Risk
77.6
Sharpe
-0.92
Luna's Score
43/100
Recommendation
Sell

Luna says (GLMD | US)

What's Working

Low Market Beta (-0.4 to 0.8)

Value Stock (Price to Book < 3)

What's not Working

Price Below SMA10D

High 6-Month Volatility (>65%)

Microcap (<300M USD)

Weak Sharpe Ratio (< 0.3)

Volatility Signals

Bearish: Increased Volatility (6-month > 1-month volatility)

Risk Meter

10 days

57.2%

1 month

77.6%

3 months

76.5%

6 months

79.2%

Returns

Fundamental Ratios

PE

-

Fwd. PE

-

Price to book

0.44

Debt to equity

-

Debt to assets

-

Ent. to EBITDA

0.32

Ent. to rev.

-

PEG

-

Other Fundamentals

EBITDA

-6.14M

MarketCap

904.19K

MarketCap(USD)

904.19K

Div. yield

-

Op. margin

-

Erngs. growth

-

Rev. growth

-

Ret. on equity

-52.67

Short ratio

-

Short perc.

2.30

Market Sentiment (SMA and Price signals)

Short-term: Bullish (SMA10D > SMA1M)

Intermediate-term: Bearish (SMA1M < SMA3M)

Long-term: Bearish (SMA6M < SMA12M)

SMAs: Stock Price Trends

Range10D

0.11

Range1M

0.19

Range3M

0.50

Volumes: Market Activity

Rel. volume

0.18

Price X volume

4.10K

Peers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
Evofem Biosciences IncEVFMBiotechnology0.0085852.80K0.000.00%
Pasithea Therapeutics Corp. Common StockKTTABiotechnology0.797832.79K1.91%n/a0.00%
Virax Biolabs Group Limited Ordinary SharesVRAXBiotechnology0.1732752.03K-4.63%n/a4.18%
Innovation Pharmaceuticals IncIPIXBiotechnology0.0008414.68K0.00%n/a20.48%
Biodexa PharmaceticalsBDRXBiotechnology0.7006406.94K2.25%n/a0.00%
Syros Pharmaceuticals IncSYRSBiotechnology0.00025.36K0.00%n/a-954.99%
XOMAPXOMAPBiotechnology25.60-0.58%26.27121.93%
XOMA Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred StockXOMAOBiotechnology25.330-0.04%25.57121.93%
Revolution Medicines Inc. WarrantRVMDWBiotechnology1.60-15.34%n/a5.40%
Rocket Pharmaceuticals Inc. WarrantRCKTWBiotechnology0.01580-21.00%n/a0.00%
  • 1

Diversifiers

Name
Ticker
Industry
Close
Marketcap
Day Return
PE Ratio
Debt to Equity
 
 
 
 
 
 
 
 
No data

Industry Comparison

ParameterCompanyIndustryIndicator
Enterprise to EBITDA0.32-Cheaper
Ent. to Revenue---
PE Ratio-41.03-
Price to Book0.4415.55Cheaper
Dividend Yield---
Std. Deviation (3M)76.46-Par
Debt to Equity--1.23-
Debt to Assets-0.25-
Market Cap904.19K-Emerging
  • 1

Unlock Your Investing Potential

Register with Xstocks

Join over 2,000+ Investors

Register now and embark on your journey to informed and successful investing.

Explore Industry Correlations

Explore Industry Correlations

Uncover Trading and Hedging Opportunities

Gain valuable insights into potential trading opportunities and discover strategic hedging possibilities

Discover Top-Performing Industries

Discover Top performing Industries

Explore Stocks for Short and Long-Term Gains

Uncover opportunities at both short-term and long-term horizons, allowing you to make informed investment decisions.

Follow us @XStocks007